No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Cotempla XR ODT is a central nervous system (CNS) drug used to treat attention-deficit/hyperactivity disorder (ADHD) in children aged 6 to 17 years. It is a once-daily, orally disintegrating tablet (ODT) that dissolves quickly in the mouth without the need for water. The drug is a stimulant that works by increasing the levels of certain chemicals in the brain that are responsible for controlling behavior and attention. It is designed to help improve focus, concentration, and impulse control in children with ADHD.
The Cotempla XR ODT market is a rapidly growing segment of the CNS drugs market. It is expected to benefit from the increasing prevalence of ADHD and the growing demand for convenient and effective treatments. The market is also expected to benefit from the increasing awareness of ADHD and the availability of new treatments.
Some of the key players in the Cotempla XR ODT market include Shire, Novartis, Teva Pharmaceuticals, and Mylan. Show Less Read more
